Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.68 |
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 4/20 | 0.66 |
| ▸ | RAD52 | P43351 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.66 |
| ▸ | HTR1A | P08908 | 3/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.66 |
| ▸ | DRD1 | P21728 | 3/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.66 |
| ▸ | DRD3 | P35462 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271320 | 0.89 | FPR2 (0.62) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL10168007 | 0.88 | FPR2 (0.72) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL4273505 | 0.88 | FPR2 (0.75) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL4279887 | 0.88 | FPR2 (0.84) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL23059754 | 0.87 | TP53 (0.71) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL10168008 | 0.87 | FPR2 (0.61) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL4283601 | 0.87 | TP53 (0.76) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL561133 | 0.87 | FPR2 (0.70) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL13346862 | 0.87 | LMNA (0.79) | FPR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL10168005 | 0.86 | FPR2 (0.64) | FPR2LMNAMAPTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| WO-2010056979-A1 | PHENOTHIAZINE DERIVATIVES FOR TREATMENT OF ASTHMA | IMMUNE CONTROL, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2010009332-A1 | BINDING AND INHIBITING 5-HT4 RECEPTOR | IMMUNE CONTROL, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009108635-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | IMMUNE CONTROL, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IL5, HRH4, TLR5 | FPR2 80/4885LMNA 3774/4885MAPT 1538/4885 |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | HTR4, HTR3B, HTR5A | FPR2 70/4885LMNA 4056/4885MAPT 3747/4885 |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | TPH1, HTR5A, HTR6 | FPR2 43/4885LMNA 1507/4885MAPT 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.